In this study, treatment of CML cells with the Roscovitine-derived inhibitors leads to increase of active forms of caspase 3 and its substrate PARP ultimately leading to cell death. The gene discussed is CASP3; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.